PATENT CLAIM ANALYSIS

Application Number: 15885975
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "254090"]

Abstract:
The disclosure also provides compositions and methods related to combination therapy with HSP90 inhibitors and BCL-2 pathway inhibitors for treating cancer. The disclosure also provides compositions and methods related to the use of low dose' HSP90 inhibitors in the treatment of cancer, alone and in combination with other therapeutic agents.

Claim (Index 17):
The method of  claim 16 , wherein the HSP90 inhibitor is MPC-0767 or tanespimycin, and pharmaceutically acceptable salts thereof.

Metadata:
- Claim Count in Document: 42.0
- Percentile: 88.0
- Lexical Diversity: 1.63636
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14131423', '15024396', '14070420', '12741884', '14438310']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7536807126130878
- 35 USC 102 Novelty (BERT): 0.5258068015437629
- Combined Prediction Score: 0.7308933215061554
- Mean Citation Score: 294.673162
- Max Citation Score: 333.61163
- Similarity Product: 240.75910633094432

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test